Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Director Sells $50,812.50 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $8.13, for a total value of $50,812.50. Following the transaction, the director directly owned 96,992 shares of the company’s stock, valued at approximately $788,544.96. This represents a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Stock Down 0.9%

Shares of NASDAQ SOPH traded down $0.07 during midday trading on Thursday, hitting $7.61. 378,522 shares of the company’s stock were exchanged, compared to its average volume of 261,546. The firm’s fifty day simple moving average is $6.93 and its 200-day simple moving average is $5.65. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The company has a market cap of $638.40 million, a PE ratio of -6.62 and a beta of 0.98. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently bought and sold shares of the business. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter valued at about $9,809,000. Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth about $1,772,000. Maven Securities LTD acquired a new position in SOPHiA GENETICS in the 2nd quarter valued at about $866,000. 1492 Capital Management LLC purchased a new stake in SOPHiA GENETICS during the 4th quarter valued at approximately $973,000. Finally, Royce & Associates LP acquired a new stake in SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on SOPH shares. HC Wainwright upped their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research boosted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.